Best Medical Treatment: What About the COMPASS Trial Strategy?

Authors

  • Sofia Rosado Julião Serviço de Medicina III. Hospital Pulido Valente. Centro Hospitalar e Universitário de Lisboa Norte. Lisboa. https://orcid.org/0000-0002-1727-1101
  • Andreia Rodrigues Lopes Serviço de Medicina III. Hospital Pulido Valente. Centro Hospitalar e Universitário de Lisboa Norte. Lisboa.
  • Mariana Alves Serviço de Medicina III. Hospital Pulido Valente. Centro Hospitalar e Universitário de Lisboa Norte. Lisboa. Faculdade de Medicina. Universidade de Lisboa. Lisboa. https://orcid.org/0000-0002-1369-8423

DOI:

https://doi.org/10.20344/amp.18879

Keywords:

Aspirin/therapeutic use, Coronary Artery Disease/drug therapy, Platelet Aggregation Inhibitors/therapeutic use, Peripheral Arterial Disease/drug therapy, Rivaroxaban/therapeutic use

Abstract

N/a.

Downloads

Download data is not yet available.

Downloads

Published

2022-08-18

How to Cite

1.
Rosado Julião S, Rodrigues Lopes A, Alves M. Best Medical Treatment: What About the COMPASS Trial Strategy?. Acta Med Port [Internet]. 2022 Aug. 18 [cited 2024 Nov. 22];35(10):777-8. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/18879

Issue

Vol. 35 No. 10 (2022): October

Section

Letters to the Editor

License

Copyright (c) 2022 Acta Médica Portuguesa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC